DNA double-strand break repair inhibitors as cancer therapeutics.

Among DNA damages, double-strand breaks (DSBs) are one of the most harmful lesions to a cell. Failure in DSB repair could lead to genomic instability and cancer. Homologous recombination (HR) and nonhomologous end joining (NHEJ) are major DSB repair pathways in higher eukaryotes. It is known that expression of DSB repair genes is altered in various cancers. Activation of DSB repair genes is one of the reasons for chemo- and radioresistance. Therefore, targeting DSB repair is an attractive strategy to eliminate cancer. Besides, therapeutic agents introduce breaks in the genome as an intermediate. Therefore, blocking the residual repair using inhibitors can potentiate the efficacy of cancer treatment. In this review, we discuss the importance of targeting DSB repair pathways for the treatment of cancer. Recent advances in the development of DSB repair inhibitors and their clinical relevance are also addressed.

[1]  H. Vogel,et al.  Deletion of Ku86 causes early onset of senescence in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Symington,et al.  Double-strand break end resection and repair pathway choice. , 2011, Annual review of genetics.

[3]  E. Swisher,et al.  Secondary mutations of BRCA1/2 and drug resistance , 2011, Cancer science.

[4]  J. Steitz,et al.  Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. , 1986, The Journal of biological chemistry.

[5]  R. Kanaar,et al.  DNA double-strand break repair: all's well that ends well. , 2006, Annual review of genetics.

[6]  Monika Aggarwal,et al.  Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress , 2011, Proceedings of the National Academy of Sciences.

[7]  K. Schwarz,et al.  The embryonic lethality in DNA ligase IV-deficient mice is rescued by deletion of Ku: implications for unifying the heterogeneous phenotypes of NHEJ mutants. , 2002, DNA repair.

[8]  Facundo D. Batista,et al.  RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection , 2013, Molecular cell.

[9]  B. Bertocci,et al.  Nonoverlapping functions of DNA polymerases mu, lambda, and terminal deoxynucleotidyltransferase during immunoglobulin V(D)J recombination in vivo. , 2006, Immunity.

[10]  F. Alt,et al.  DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. , 2000, Molecular cell.

[11]  S. Powell,et al.  Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic Advancement , 2012, Clinical Cancer Research.

[12]  Ralph Scully,et al.  Role of mammalian Mre11 in classical and alternative non-homologous end joining , 2009, Nature Structural &Molecular Biology.

[13]  Maximina H. Yun,et al.  CtIP-BRCA1 modulates the choice of DNA double-strand break repair pathway throughout the cell cycle , 2009, Nature.

[14]  P. Jeggo,et al.  Double strand break rejoining by the Ku-dependent mechanism of non-homologous end-joining. , 1999, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[15]  C. Koch,et al.  Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and γ radiation , 2005, Molecular Cancer Therapeutics.

[16]  R. Kanaar,et al.  Homologous recombination-mediated double-strand break repair. , 2004, DNA repair.

[17]  E. Synowiec,et al.  BLM and RAD51 Genes Polymorphism and Susceptibility to Breast Cancer , 2013, Pathology & Oncology Research.

[18]  D. Spitz,et al.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy. , 2009, Journal of cancer research and therapeutics.

[19]  R. Kanaar,et al.  Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition , 2011, Proceedings of the National Academy of Sciences.

[20]  M. Rydzanicz,et al.  The MRN protein complex genes: MRE11 and RAD50 and susceptibility to head and neck cancers , 2013, Molecular Cancer.

[21]  B. Zhivotovsky,et al.  DNA-dependent protein kinase content and activity in lung carcinoma cell lines: correlation with intrinsic radiosensitivity. , 1999, European journal of cancer.

[22]  John A Tainer,et al.  DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. , 2014, Molecular cell.

[23]  K. Tew,et al.  Increased expression of DNA-dependent protein kinase confers resistance to adriamycin. , 1998, Biochimica et biophysica acta.

[24]  Wolf-Dietrich Heyer,et al.  Homologous recombination in DNA repair and DNA damage tolerance , 2008, Cell Research.

[25]  M. Tilby,et al.  A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. , 2004, Blood.

[26]  G. Chu,et al.  Processing of DNA for Nonhomologous End-joining Is Controlled by Kinase Activity and XRCC4/Ligase IV* , 2007, Journal of Biological Chemistry.

[27]  Lino Tessarollo,et al.  Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice , 2001, Current Biology.

[28]  J. Bourhis,et al.  Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen. , 1999, Molecular pharmacology.

[29]  J. Lowe,et al.  Pediatric brain tumor cancer stem cells: cell cycle dynamics, DNA repair, and etoposide extrusion , 2010, Neuro-oncology.

[30]  S. Kowalczykowski,et al.  Two classes of BRC repeats in BRCA2 promote RAD51 nucleoprotein filament function by distinct mechanisms , 2011, Proceedings of the National Academy of Sciences.

[31]  D. Barnes,et al.  Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice , 1998, Current Biology.

[32]  N. Tolliday,et al.  Analysis of the Activities of RAD54, a SWI2/SNF2 Protein, Using a Specific Small-molecule Inhibitor* , 2013, The Journal of Biological Chemistry.

[33]  S. West,et al.  Defective DNA Repair and Neurodegenerative Disease , 2007, Cell.

[34]  M. Bower,et al.  Structural Basis for Chk1 Inhibition by UCN-01* , 2002, The Journal of Biological Chemistry.

[35]  C. Anderson,et al.  DNA-dependent protein kinase is activated by nicks and larger single-stranded gaps. , 1994, The Journal of biological chemistry.

[36]  D. Barnes,et al.  Molecular cloning and expression of human cDNAs encoding a novel DNA ligase IV and DNA ligase III, an enzyme active in DNA repair and recombination , 1995, Molecular and cellular biology.

[37]  D. Cortez.  Caffeine Inhibits Checkpoint Responses without Inhibiting the Ataxia-Telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) Protein Kinases* , 2003, Journal of Biological Chemistry.

[38]  Akira Shinohara,et al.  Rad51‐deficient vertebrate cells accumulate chromosomal breaks prior to cell death , 1998, The EMBO journal.

[39]  J. Sidorova.  Roles of the Werner syndrome RecQ helicase in DNA replication. , 2008, DNA repair.

[40]  T. Pandita,et al.  Rad52 inactivation is synthetically lethal with BRCA2 deficiency , 2010, Proceedings of the National Academy of Sciences.

[41]  A. Bradley,et al.  Disruption of mRad50 causes embryonic stem cell lethality, abnormal embryonic development, and sensitivity to ionizing radiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Feldman,et al.  Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 , 2010, Genetics in Medicine.

[43]  Lei Zhang,et al.  DNA Ligase III Promotes Alternative Nonhomologous End-Joining during Chromosomal Translocation Formation , 2011, PLoS genetics.

[44]  Jayanta Chaudhuri,et al.  CtIP promotes microhomology-mediated alternative end-joining during class switch recombination , 2010, Nature Structural &Molecular Biology.

[45]  T. Helleday.  Homologous recombination in cancer development, treatment and development of drug resistance. , 2010, Carcinogenesis.

[46]  T. Helleday,et al.  The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer , 2003, International journal of cancer.

[47]  B. Morolli,et al.  Targeted Inactivation of Mouse RAD52Reduces Homologous Recombination but Not Resistance to Ionizing Radiation , 1998, Molecular and Cellular Biology.

[48]  D. Januszkiewicz-Lewandowska,et al.  Association of the heterozygous germline I171V mutation of the NBS1 gene with childhood acute lymphoblastic leukemia , 2006, Leukemia.

[49]  Jeremy M. Stark,et al.  RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells , 2012, Nucleic acids research.

[50]  P. Sung,et al.  Mechanism of eukaryotic homologous recombination. , 2008, Annual review of biochemistry.

[51]  A. Tomkinson,et al.  Human Mre11/Human Rad50/Nbs1 and DNA Ligase IIIα/XRCC1 Protein Complexes Act Together in an Alternative Nonhomologous End Joining Pathway* , 2011, The Journal of Biological Chemistry.

[52]  Nicola J. Curtin,et al.  DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.

[53]  Barbara Corneo,et al.  Rag mutations reveal robust alternative end joining , 2007, Nature.

[54]  T. Chow,et al.  An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. , 2002, Cancer research.

[55]  A. Jauch,et al.  DNA Ligase IV-Dependent NHEJ of Deprotected Mammalian Telomeres in G1 and G2 , 2002, Current Biology.

[56]  M. Gellert,et al.  DNA binding of Xrcc4 protein is associated with V(D)J recombination but not with stimulation of DNA ligase IV activity , 1999, The EMBO journal.

[57]  Jean Gautier,et al.  Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells , 2009, Nature Structural &Molecular Biology.

[58]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[59]  P. Jeggo,et al.  A Ku80 fragment with dominant negative activity imparts a radiosensitive phenotype to CHO-K1 cells. , 2000, Nucleic acids research.

[60]  P. Gregersen,et al.  BLM Heterozygosity and the Risk of Colorectal Cancer , 2002, Science.

[61]  Sheetal Sharma,et al.  Nonhomologous DNA End Joining in Cell-Free Extracts , 2010, Journal of nucleic acids.

[62]  Yunmei Ma,et al.  Hairpin Opening and Overhang Processing by an Artemis/DNA-Dependent Protein Kinase Complex in Nonhomologous End Joining and V(D)J Recombination , 2002, Cell.

[63]  N. Curtin,et al.  Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. , 2003, Cancer research.

[64]  Eric A. Hendrickson,et al.  Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells , 2010, PLoS genetics.

[65]  D. Melton,et al.  DNA repair endonuclease ERCC1–XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy , 2012, Nucleic acids research.

[66]  C. Beskow,et al.  Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86 , 2009, British Journal of Cancer.

[67]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[68]  T. Stamato,et al.  Absence of DNA ligase IV protein in XR-1 cells: evidence for stabilization by XRCC4. , 1999, Mutation research.

[69]  J. Hoeijmakers,et al.  Disruption of Mouse RAD54 Reduces Ionizing Radiation Resistance and Homologous Recombination , 1997, Cell.

[70]  Michal Zimmermann,et al.  53BP1: pro choice in DNA repair. , 2014, Trends in cell biology.

[71]  M. Lieber,et al.  DNA ligase IV binds to XRCC4 via a motif located between rather than within its BRCT domains , 1998, Current Biology.

[72]  P. Jeggo,et al.  Targeted disruption of the catalytic subunit of the DNA-PK gene in mice confers severe combined immunodeficiency and radiosensitivity. , 1998, Immunity.

[73]  S. Kowalczykowski,et al.  Rad52 protein stimulates DNA strand exchange by Rad51 and replication protein A , 1998, Nature.

[74]  Jean Gautier,et al.  A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. , 2008, Nature chemical biology.

[75]  Fiona A. Stewart,et al.  Strategies to improve radiotherapy with targeted drugs , 2011, Nature Reviews Cancer.

[76]  H. Arakawa,et al.  Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. , 2005, Cancer research.

[77]  G. Mills,et al.  Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. , 2008, Cancer research.

[78]  A. De,et al.  An Inhibitor of Nonhomologous End-Joining Abrogates Double-Strand Break Repair and Impedes Cancer Progression , 2012, Cell.

[79]  Paul Modrich,et al.  BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. , 2011, Genes & development.

[80]  K. Kohn,et al.  Ataxia telangiectasia mutated activation by transcription‐ and topoisomerase I‐induced DNA double‐strand breaks , 2009, EMBO reports.

[81]  S. Brill,et al.  Slx1-Slx4 is a second structure-specific endonuclease functionally redundant with Sgs1-Top3. , 2003, Genes & development.

[82]  M. Lieber,et al.  The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. , 2010, Annual review of biochemistry.

[83]  L. Niedernhofer,et al.  ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer , 2011, Pharmacogenomics and personalized medicine.

[84]  S. Diamond,et al.  Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. , 2011, ACS chemical biology.

[85]  K. Nakashiro,et al.  Up‐regulation of DNA‐dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma , 2003, Cancer science.

[86]  I. Ayene,et al.  Glucose deprivation increases nuclear DNA repair protein Ku and resistance to radiation induced oxidative stress in human cancer cells , 2009, Cell biochemistry and function.

[87]  Stephen P. Jackson,et al.  A means to a DNA end: the many roles of Ku , 2004, Nature Reviews Molecular Cell Biology.

[88]  Y. Furuichi,et al.  RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma. , 2011, Cancer research.

[89]  S. Chiou,et al.  Overexpression of NBS1 induces epithelial–mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer , 2007, Oncogene.

[90]  Richard Svensson,et al.  MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool , 2014, Nature.

[91]  Michael M. Murphy,et al.  IgH class switching and translocations use a robust non-classical end-joining pathway , 2007, Nature.

[92]  J. Walker,et al.  Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair , 2001, Nature.

[93]  P. Jeggo,et al.  Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient , 1999, Current Biology.

[94]  J. Jonkers,et al.  Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects , 2006, Oncogene.

[95]  P. Sung,et al.  Regulation of Rad51 Recombinase Presynaptic Filament Assembly via Interactions with the Rad52 Mediator and the Srs2 Anti-recombinase* , 2009, The Journal of Biological Chemistry.

[96]  Ian D. Hickson,et al.  The Bloom's syndrome helicase suppresses crossing over during homologous recombination , 2003, Nature.

[97]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[98]  A. Fischer,et al.  Artemis, a Novel DNA Double-Strand Break Repair/V(D)J Recombination Protein, Is Mutated in Human Severe Combined Immune Deficiency , 2001, Cell.

[99]  J. Yates,et al.  Mus81-Eme1 Are Essential Components of a Holliday Junction Resolvase , 2001, Cell.

[100]  George Iliakis,et al.  PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways , 2006, Nucleic acids research.

[101]  A. Kozikowski,et al.  An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. , 2013, Journal of medicinal chemistry.

[102]  D. Weaver,et al.  Conditional gene targeted deletion by Cre recombinase demonstrates the requirement for the double-strand break repair Mre11 protein in murine embryonic stem cells. , 1997, Nucleic acids research.

[103]  T. Paull,et al.  Nbs1 potentiates ATP-driven DNA unwinding and endonuclease cleavage by the Mre11/Rad50 complex. , 1999, Genes & development.

[104]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[105]  Marco Foiani,et al.  Regulation of DNA repair throughout the cell cycle , 2008, Nature Reviews Molecular Cell Biology.

[106]  S. Raghavan,et al.  How does DNA break during chromosomal translocations? , 2011, Nucleic acids research.

[107]  A. Tomkinson,et al.  Eukaryotic DNA ligases: structural and functional insights. , 2008, Annual review of biochemistry.

[108]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[109]  M. Lieber,et al.  XRCC4:DNA ligase IV can ligate incompatible DNA ends and can ligate across gaps , 2007, The EMBO journal.

[110]  W. Heyer,et al.  Rad54, a Swi2/Snf2-like recombinational repair protein, disassembles Rad51:dsDNA filaments. , 2002, Molecular cell.

[111]  H. Lieberman.  DNA damage repair and response proteins as targets for cancer therapy. , 2008, Current medicinal chemistry.

[112]  N. Oliveira,et al.  DNA-PK inhibitor wortmannin enhances DNA damage induced by bleomycin in V79 Chinese hamster cells. , 2002, Teratogenesis, carcinogenesis, and mutagenesis.

[113]  R. Brosh,et al.  Helicases as prospective targets for anti-cancer therapy. , 2008, Anti-cancer agents in medicinal chemistry.

[114]  Molly A Bogue,et al.  Ku86-Deficient Mice Exhibit Severe Combined Immunodeficiency and Defective Processing of V(D)J Recombination Intermediates , 1996, Cell.

[115]  Rolando Perez-Pineiro,et al.  Small Molecule Inhibitors of ERCC1-XPF Protein-Protein Interaction Synergize Alkylating Agents in Cancer Cells , 2013, Molecular Pharmacology.

[116]  D. Papadopoulo,et al.  The influence of DNA double-strand break structure on end-joining in human cells. , 2001, Nucleic acids research.

[117]  F. Alt,et al.  Leaky Scid phenotype associated with defective V(D)J coding end processing in Artemis-deficient mice. , 2002, Molecular cell.

[118]  F. Alt,et al.  Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development , 2000, Nature.

[119]  M. Kastan,et al.  Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. , 2008, Cancer research.

[120]  Daniel Medina,et al.  Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. , 2008, Cancer research.

[121]  M. Gallucci,et al.  Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies , 2001, Oncogene.

[122]  G. Superti-Furga,et al.  Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy , 2014, Nature.

[123]  Andrei Seluanov,et al.  DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells , 2008, Cell cycle.

[124]  A. Sancar,et al.  Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. , 2004, Annual review of biochemistry.

[125]  Jack W. Szostak,et al.  The double-strand-break repair model for recombination , 1983, Cell.

[126]  M. McVey,et al.  MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. , 2008, Trends in genetics : TIG.

[127]  T. Kunkel,et al.  A gradient of template dependence defines distinct biological roles for family X polymerases in nonhomologous end joining. , 2005, Molecular cell.

[128]  R. Hromas,et al.  Synthetic lethality: exploiting the addiction of cancer to DNA repair. , 2011, Blood.

[129]  L. Symington,et al.  RPA coordinates DNA end resection and prevents formation of DNA hairpins. , 2013, Molecular cell.

[130]  F. Alt,et al.  Unrepaired DNA Breaks in p53-Deficient Cells Lead to Oncogenic Gene Amplification Subsequent to Translocations , 2002, Cell.

[131]  E. Blackburn,et al.  Ku is associated with the telomere in mammals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[132]  Y. Shiloh,et al.  Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. , 1997, Annual review of genetics.

[133]  D. Baltimore,et al.  ATR disruption leads to chromosomal fragmentation and early embryonic lethality. , 2000, Genes & development.

[134]  Linda Z. Shi,et al.  Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells , 2013, Proceedings of the National Academy of Sciences.

[135]  K. Rosenzweig,et al.  Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[136]  Paul D P Pharoah,et al.  Variants in DNA double-strand break repair genes and breast cancer susceptibility. , 2002, Human molecular genetics.

[137]  F. Alt,et al.  Mechanisms that promote and suppress chromosomal translocations in lymphocytes. , 2011, Annual review of immunology.

[138]  F. Hutchinson,et al.  Chemical changes induced in DNA by ionizing radiation. , 1985, Progress in nucleic acid research and molecular biology.

[139]  E. Kolker,et al.  Competition between PARP-1 and Ku70 control the decision between high-fidelity and mutagenic DNA repair. , 2011, DNA repair.

[140]  M. Jasin,et al.  Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4/ligase IV during chromosomal translocation formation , 2010, Nature Structural &Molecular Biology.

[141]  James R Bischoff,et al.  A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations , 2011, Nature Structural &Molecular Biology.

[142]  J. Darbon,et al.  Distinct Chk2 Activation Pathways Are Triggered by Genistein and DNA-damaging Agents in Human Melanoma Cells* , 2000, The Journal of Biological Chemistry.

[143]  T. Paull,et al.  The 3' to 5' exonuclease activity of Mre 11 facilitates repair of DNA double-strand breaks. , 1998, Molecular cell.

[144]  I. Vancurova,et al.  A DNA-activated protein kinase from HeLa cell nuclei , 1990, Molecular and cellular biology.

[145]  G. Chu,et al.  Cernunnos/XLF promotes the ligation of mismatched and noncohesive DNA ends , 2007, Proceedings of the National Academy of Sciences.

[146]  M. Lieber,et al.  Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells , 1997, Nature.

[147]  K. Khanna,et al.  Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice , 2014, Nature Communications.

[148]  Maureen E. Hoatlin,et al.  Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics , 2012, Anemia.

[149]  K. Valerie,et al.  Regulation and mechanisms of mammalian double-strand break repair , 2003, Oncogene.

[150]  J. Sarkaria,et al.  Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines , 2011, British Journal of Cancer.

[151]  N. Curtin,et al.  Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.

[152]  B. Price,et al.  The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. , 1996, Cancer research.

[153]  Wei Yan,et al.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.

[154]  D. Ramsden,et al.  Polymerase Mu Is a DNA-Directed DNA/RNA Polymerase , 2003, Molecular and Cellular Biology.

[155]  S. Jackson,et al.  Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV , 1997, Current Biology.

[156]  Francis Collins,et al.  Atm-Deficient Mice: A Paradigm of Ataxia Telangiectasia , 1996, Cell.

[157]  C. Harris,et al.  A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. , 2013, Chemistry & biology.

[158]  S. Powell,et al.  Targeting the DNA damage response for cancer therapy. , 2009, DNA repair.

[159]  Michael B Yaffe,et al.  Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy. , 2012, Progress in molecular biology and translational science.

[160]  M. Hande,et al.  Effects of DNA nonhomologous end-joining factors on telomere length and chromosomal stability in mammalian cells , 2001, Current Biology.

[161]  David J. Chen,et al.  A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining. , 2008, The Journal of clinical investigation.

[162]  Dihua Yu,et al.  Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation , 2007, Molecular Cancer Therapeutics.

[163]  J. Hoeijmakers,et al.  ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair , 2008, Molecular and Cellular Biology.

[164]  H. Arakawa,et al.  DNA Ligases I and III Cooperate in Alternative Non-Homologous End-Joining in Vertebrates , 2013, PloS one.

[165]  R. Kanaar,et al.  Targeting homologous recombination-mediated DNA repair in cancer , 2014, Expert opinion on therapeutic targets.

[166]  S. West,et al.  Identification of Holliday junction resolvases from humans and yeast , 2008, Nature.

[167]  M. Lieber,et al.  Yeast DNA ligase IV mediates non-homologous DNA end joining , 1997, Nature.

[168]  Alexander D. MacKerell,et al.  Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. , 2008, Cancer research.

[169]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[170]  F. Alt,et al.  Alternative end-joining catalyzes class switch recombination in the absence of both Ku70 and DNA ligase 4 , 2010, The Journal of experimental medicine.